ライフサイエンスコーパス: cellular immunity

1 be used to elicit human anti-RSV humoral and cellular immunity.

2 ovel function for nonhuman TRIM5 variants in cellular immunity.

3 Toll-like receptor 9 agonist, which augments cellular immunity.

4 sign HIV-1 vaccines that stimulate effective cellular immunity.

5 s that contain important targets of anti-HIV cellular immunity.

6 hift the vaccination immune response towards cellular immunity.

7 comitantly to effector Th cells that support cellular immunity.

8 ent on DCs to stimulate long-term anti-tumor cellular immunity.

9 responses, and 1V270 potently generates Th1 cellular immunity.

10 stemic corticosteroid therapy, which impairs cellular immunity.

11 expression, including many genes involved in cellular immunity.

12 erized vector for inducing both antibody and cellular immunity.

13 ials, likely due to inefficient induction of cellular immunity.

14 ing cell 'spreading', an initiating event in cellular immunity.

15 ing CD40 failed to produce either humoral or cellular immunity.

16 elopment of vaccines that efficiently target cellular immunity.

17 tion of balanced Th-1 polarization and Th-17 cellular immunity.

18 antigens, because of their ability to induce cellular immunity.

19 vant dose for inducing potent and long-lived cellular immunity.

20 esponses but are more limited for generating cellular immunity.

21 ensively explored concept aimed at improving cellular immunity.

22 ly therapeutic approach to enhance antiviral cellular immunity.

23 nt (allo-BMT) is controlled by donor-derived cellular immunity.

24 dow of time for the generation of protective cellular immunity.

25 on with heterologous vaccines elicits potent cellular immunity.

26 icity, cross-reactivity, and antigenicity in cellular immunity.

27 by the paucity of information on targets of cellular immunity.

28 spected to protect HIV-1-infected cells from cellular immunity.

29 calcium bursts as an important aspect of fly cellular immunity.

30 vor epigenetic reprogramming and escape from cellular immunity.

31 ox vaccine recipients with severely impaired cellular immunity.

32 valuate kidney damage, humoral immunity, and cellular immunity.

33 activation of Ab-induced innate or adaptive cellular immunity.

34 m which to identify correlates of protective cellular immunity.

35 nate signaling pathways, could elicit strong cellular immunity.

36 nd adjuvant followed by NYVAC elicits potent cellular immunity.

37 be an effective vaccine formula in inducing cellular immunity.

38 oute in induction of systemic HIV-1-specific cellular immunity.

39 er therapeutic strategy via up-regulation of cellular immunity.

40 s with concomitant engagement of humoral and cellular immunity.

41 yield greater IL-27 production and sustained cellular immunity.

42 rAd)-based vectors can induce potent mucosal cellular immunity.

43 e overcome through the induction of enhanced cellular immunity.

44 d animals, suggesting an effect of rEV576 on cellular immunity.

45 important link between humoral immunity and cellular immunity.

46 eptors (FcR) on APCs can enhance humoral and cellular immunity.

47 athways of innate immunity and induce strong cellular immunity.

48 resulting in enhanced and prolonged effector cellular immunity.

49 initiate and maintain effective humoral and cellular immunity.

50 se interactions are important in humoral and cellular immunity.

51 icipatory role for this unique population in cellular immunity.

52 tes with strong pretransplant donor-reactive cellular immunity.

53 , therefore providing a potential target for cellular immunity.

54 as a means to induce Ag-specific humoral and cellular immunity.

55 of migratory behavior in DCs for protective cellular immunity.

56 erologous prime-boost regimens induce potent cellular immunity.

57 rough multiple effectors of both humoral and cellular immunity.

58 med that CCR7 is critical for PI-WCV-induced cellular immunity.

59 ation whether it was evaluated by humoral or cellular immunity.

60 ry T cells that form the basis of protective cellular immunity.

61 nts a potent vaccine adjuvant of humoral and cellular immunity.

62 erving sufficient normal T cells to maintain cellular immunity.

63 hrough chromatinization as part of intrinsic cellular immunity.

64 conserved receptor that limits and redirects cellular immunity.

65 chanisms of these drugs and their effects on cellular immunity.

66 may benefit parasite escape from humoral and cellular immunity.

67 up, activates NF-kappaB-mediated humoral and cellular immunity.

68 cterial peritonitis, known to have defective cellular immunity.

69 cant part of transferred immunity is passive cellular immunity.

70 d cell surface to escape recognition by host cellular immunity.

71 PA axis, which modulate spleen shrinkage and cellular immunity.

72 iferation and plant growth at the expense of cellular immunity.

73 IV B clade fusion protein designed to induce cellular immunity.

74 e development will augment either humoral or cellular immunity.

75 nal immunity" to distinguish it from passive cellular immunity.

76 , who championed the role of phagocytosis in cellular immunity.

77 tibodies, but with no detectable GP-directed cellular immunity.

78 T cell dichotomy is essential for effective cellular immunity.

79 echanism for fine-tuning and optimization of cellular immunity.

80 In contrast to the effect on cellular immunity, Ab responses were comparable between

81 -33 did not compromise alum-induced adaptive cellular immunity after i.m. vaccination.

82 e of priming may be a strategy for improving cellular immunity after vaccination.

83 ponses are valuable tools to shape and drive cellular immunity against cancer and intracellular infec

84 which elicited robust humoral, mucosal, and cellular immunity against diverse virus strains.

85 d the potential of pDCs to trigger antiviral cellular immunity against HBV.

86 esponses and suggest that enhancing adaptive cellular immunity against HEV might prevent persistent H

87 latform to induce strong mucosal humoral and cellular immunity against HIV.

88 ory approaches aimed at harnessing cytotoxic cellular immunity against HIV.

89 ontribute to the induction and activation of cellular immunity against intracellular pathogens, such

90 sis in CD4(pos)CD8(pos) thymocytes modulates cellular immunity against PRRSV and other pathogens.

91 , indicating that MV-NIS treatment triggered cellular immunity against the patients' tumor and sugges

92 magglutinin antigen induction of humoral and cellular immunity against viral challenges.

93 Cellular immunity against viral infection and tumour cel

94 ding cassette (ABC) transporter essential to cellular immunity against viral infection.

95 the unique potential to activate humoral and cellular immunity, an actual challenge is to increase pl

96 both a novel strategy of virus evasion from cellular immunity and a novel role for a cellular protei

97 es with the polyfunctionality and potency of cellular immunity and are a prime example of the potenti

98 dendritic cells (DCs) are key components of cellular immunity and are thought to originate and renew

99 red surprising molecular mechanisms in human cellular immunity and autoimmunity.

100 nfection enabled the development of adaptive cellular immunity and clearance of virus.

101 um suggested that POLR3A mutations triggered cellular immunity and cross-reactive humoral immune resp

102 The microbiome plays an important role in cellular immunity and energy metabolism and has been imp

103 tein boosting, elicited systemic and mucosal cellular immunity and exhibited equivalent, significant

104 So far, viral targets of cellular immunity and factors determining successful mou

105 a regulatory connectome of genes related to cellular immunity and fibrosis.

106 Mtb) results in the generation of protective cellular immunity and formation of granulomatous structu

107 by envelope protein boosting, elicits broad cellular immunity and functional, envelope-specific seru

108 into the basic biology of adjuvant-elicited cellular immunity and have clear implications for the sc

109 a key modulator of viral adaptation to host cellular immunity and highlight the power of combined bi

110 de that MCP-1 plays a key role in regulating cellular immunity and IFN-gamma production following pne

111 n of the same HLA alleles in vaccine-induced cellular immunity and in natural immune control is of re

112 e association with progressive impairment of cellular immunity and increasing susceptibility to oppor

113 he early stage of HIV infection, humoral and cellular immunity and innate immune functions in oral mu

114 ghts relationships between humoral immunity, cellular immunity and nonadherence.

115 of autologous transfer strategies to explore cellular immunity and potential therapeutic applications

116 (LdCen(-/-) and Ldp27(-/-)) induce a strong cellular immunity and provide protection against viscera

117 s reported along with phenotypic analysis of cellular immunity and quantitation of humoral immunity.

118 his may prove useful in monitoring patients' cellular immunity and recovery from active BKV infection

119 The recognition events that mediate adaptive cellular immunity and regulate antibody responses depend

120 M and Mycobacterium tuberculosis is based on cellular immunity and relies on the type-1 cytokine path

121 de evidence for transplacental regulation of cellular immunity and suggest that IL-10 may influence T

122 hat vaccine-induced MDSCs inhibit protective cellular immunity and suggest that preventing MDSC induc

123 boosting elicits enhanced intestinal mucosal cellular immunity and that oral or ileal vector delivery

124 animals provide a unique model for exploring cellular immunity and the control of SIV infection and f

125 a detailed characterization of SIV-specific cellular immunity and viral control in the first 6 mo fo

126 an the other two strains in both humoral and cellular immunities, and their tumor growth was signific

127 ied loss of tissue integrity, recognition by cellular immunity, and cell death are all buffered by bl

128 orally coinciding with onset of SIV-specific cellular immunity, and elevated plasma Th1 cytokine and

129 for infectious agents boost humoral but not cellular immunity, and have poorly-understood mechanisms

130 e is characterized by inflammation, impaired cellular immunity, and immunosenescence.

131 JCV reactivation in the setting of impaired cellular immunity, and no antiviral therapies are availa

132 microaggregations were quantified for female cellular immunity, and phenoloxidase, involved in melani

133 dy pTreg, the cross-talk between humoral and cellular immunity, and regulation of the inflammatory re

134 gen dose; using novel adjuvants; stimulating cellular immunity; and targeting other viral proteins, i

135 s suggest that the acute phase and activated cellular immunity are associated with increased cellular

136 Humoral and cellular immunity are both implicated, patients express

137 munization, the roles of ICAM-1 in antiviral cellular immunity are less well understood.

138 range of autoantibodies, but the targets of cellular immunity are not well defined.

139 didate providing broad antiviral humoral and cellular immunity as a foundation for future development

140 He was the first to demonstrate cellular immunity as the immunopathological basis of per

141 lso exhibits adjuvant effects on humoral and cellular immunity as well as an enhancement of polyinosi

142 eate what is known about innate and adaptive cellular immunity as well as the downstream effector cyt

143 ill and vaccinated subjects retained strong cellular immunity, as indicated by high levels of mucosa

144 r of vitamin B-6 catabolism during activated cellular immunity, as predictors of mortality.

145 Here, we sought cellular immunity-based correlates of malaria protection

146 oped strong mucosal and systemic humoral and cellular immunity but did not exhibit delayed acquisitio

147 ill have to appropriately stimulate not only cellular immunity, but also humoral immunity.

148 the evidence that triggering of TA-specific cellular immunity by TA-targeted mAb, in conjunction wit

149 macrophage death, as well as, activation of cellular immunity by the TA, causing increased T-cell ac

150 available rather early during the pandemic, cellular immunity came into focus of investigations just

151 to validate these findings and determine if cellular immunity can be harnessed to prevent the establ

152 re studies should examine if vaccine-induced cellular immunity can prevent systemic viral replication

153 of the lamellocyte lineage following active cellular immunity caused by wasp infestation.

154 stinal nematodes is associated with impaired cellular immunity, characterized by reduced lymphocyte p

155 Cellular immunity, chiefly the CD8(+) T-cell response, p

156 could induce the durable, robust humoral and cellular immunity commonly seen in CMV seropositive subj

157 munodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 re

158 IFN-gamma plays a central role in activating cellular immunity, controlling cell proliferation, and i

159 While cellular immunity correlates with protection from clinic

160 Induction of cellular immunity could be optimized by targeted activat

161 The findings suggest dysregulated cellular immunity damages astrocytes at foci along the C

162 s infection has been regarded as inferior to cellular immunity directed to the intracellular pathogen

163 rs as critical stromal factors in regulating cellular immunity during autoimmune hepatitis.

164 The critical role of cellular immunity during tuberculosis (TB) has been exte

165 this prime-boost strategy can induce strong cellular immunity, especially in vaginal tissues, and mi

166 Because granulomas form when cellular immunity fails to clear antigenic stimuli, atte

167 e show that PrfA*(G155S) enhanced functional cellular immunity following an intravenous or intramuscu

168 of innate immunity and HER2/neu humoral and cellular immunity following cryoablation with or without

169 tanding the relationship between humoral and cellular immunity following immunization with conjugate

170 to the development of protective humoral and cellular immunity following vaccination.

171 However, the importance of humoral and cellular immunity for protection against infection with

172 , and current efforts focus on understanding cellular immunity for targeted vaccine development.

173 hydrates while suppressing genes involved in cellular immunity (gamma interferon [IFN-gamma] and the

174 Agnostic functional networks related to cellular immunity, gene expression, cell growth/prolifer

175 umab, PD-1-antibody, can enhance antimyeloma cellular immunity generated by pomalidomide, leading to

176 udy was initiated to evaluate the breadth of cellular immunity generated through immunization of rhes

177 Cellular immunity has an inherent high level of function

178 though the contribution of TRIM5 proteins to cellular immunity has not yet been studied, their intera

179 ibody affinity maturation, but their role in cellular immunity has remained unclear.

180 roperties of stem cells to maintain lifelong cellular immunity have been hypothesized for many years,

181 dies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test

182 ected hosts despite CMV-specific humoral and cellular immunity; however, how it does so remains undef

183 oad occurrence of CD40L(+) CD8(+) T cells in cellular immunity implicates that helper functions are n

184 mechanism couples innate viral sensing with cellular immunity in a single protein and could be explo

185 ly, whereas the kinetics of the SIV-specific cellular immunity in breast milk mirrored that of the bl

186 pamycin can also stimulate pathogen-specific cellular immunity in certain circumstances.

187 antigens in order to investigate defects in cellular immunity in cirrhosis.

188 Although earlier research implicated cellular immunity in dengue immunopathogenesis, a wealth

189 carriers is a potential approach to improve cellular immunity in flu vaccination.

190 an elicit potentially important SIV-specific cellular immunity in foreskin.

191 blish the level of L. monocytogenes-specific cellular immunity in healthy adults, and, together with

192 vant formulations fail to induce substantial cellular immunity in humans.

193 platform for the study of norovirus-induced cellular immunity in humans.

194 ut to investigate the role of humoral versus cellular immunity in rVSV vaccine-mediated protection ag

195 be a potential therapeutic target to restore cellular immunity in septic patients.

196 (MHC)-matched animals to assess the role of cellular immunity in SIVmac239Deltanef protection.

197 SNPs in cytokine/cytokine receptor genes and cellular immunity in subjects following primary smallpox

198 ctive comparison of M. tuberculosis-specific cellular immunity in subjects with active tuberculosis a

199 e with SARS-CoV-2, which suggests a role for cellular immunity in the context of waning or subprotect

200 aerosol rAd immunization to generate potent cellular immunity in the lung suggests that using differ

201 emory T cell recruitment for the efficacy of cellular immunity in the lung.

202 rets, all vaccinated ferrets showed improved cellular immunity in the lungs and peripheral blood.

203 e required for optimal T cell activation and cellular immunity in this in vivo nonlymphoid tumor mode

204 y adults with Ty21a and assessed humoral and cellular immunity in vaccinated volunteers and controls

205 e, a differential requirement for humoral vs cellular immunity in vaccine-induced protection against

206 ultiple-route DNA vaccinations induce strong cellular immunity, in addition to potent and high-avidit

207 IVIG has a much broader ability to regulate cellular immunity including innate and adaptive componen

208 persistent high-level viremia and defective cellular immunity, including a lack of functional HCV-sp

209 gous viral vector regimen to elicit nAbs and cellular immunity, including CD8(+) tissue-resident memo

210 Lenalidomide significantly upregulates cellular immunity, including NK and LAK activity.

211 nical testing of vaccines designed to induce cellular immunity, including those against influenza vir

212 infectious challenge, research in pursuit of cellular immunity-inducing vaccine adjuvants should no l

213 ay was conducted to further confirm a robust cellular immunity invoked by STn-PS A1.

214 of CMV infection is largely accounted for by cellular immunity, involving various T-cell and B-cell s

215 ost of varicella zoster virus (VZV)-specific cellular immunity is a likely mechanism of action.

216 Cellular immunity is critical for controlling intracellu

217 Our results demonstrate that cellular immunity is crucial to mediate cross-protection

218 cells (DC) to mediate CD4(+) T cell help for cellular immunity is guided by instructive signals recei

219 Adaptive cellular immunity is initiated by antigen-specific inter

220 variability and extent of cetuximab-mediated cellular immunity is not fully understood.

221 Cellular immunity is pivotal in HIV-1 pathogenesis but i

222 We aimed to define whether ADH-specific cellular immunity is present in alcoholic hepatitis.

223 ngle adjuvant that enhances both humoral and cellular immunity is rare and thus underlines the import

224 ong-standing notion that humoral rather than cellular immunity is sufficient to facilitate Lyme disea

225 Innate cellular immunity is the immediate host response against

226 Passive cellular immunity is well accepted and has been demonstr

227 adjuvant for enhancing antiviral humoral and cellular immunity, leading to enhanced protection agains

228 lar immune responses in eukaryotes, and this cellular immunity likely involves changes in subcellular

229 xperiment to determine whether crossreactive cellular immunity limits symptomatic illness in antibody

230 ected subjects exhibit perturbed humoral and cellular immunity, manifesting as recurrent infections,

231 lar rAd5-Env boosting increased Env-specific cellular immunity markedly in mucosal as well as systemi

232 nti-envelope (anti-Env) antibodies, and that cellular immunity may affect viral loads but not acquisi

233 d suggest that crosstalk between the CNS and cellular immunity may be a general mechanism by which in

234 A vaccine that induces both humoral and cellular immunity may be required to prevent congenital

235 Given evidence suggesting that cellular immunity may play a role in viral suppression,

236 agglutination-inhibiting (HI) antibodies and cellular immunity measured by ex vivo leukocyte response

237 S) serotype-specific capsular polysaccharide cellular immunity, measured with enzyme-linked immunospo

238 tibodies, there is substantial evidence that cellular immunity mediated by CD8(+) T cells can sustain

239 CMV-specific cellular immunity might directly contribute to this proc

240 gens; however, the impact of vector-specific cellular immunity on subsequent insert-specific T cell r

241 Because cellular immunity plays a key role in the control of the

242 Finally, pretransplant assays of anti-CMV cellular immunity predicted post-transplant CMV replicat

243 sponses in the lungs explains why protective cellular immunity quickly declines following influenza v

244 ose of the control monkeys while MV-directed cellular immunity reached levels at least as high as in

245 Evidence of long-lasting cellular immunity, regardless of anti-HBs level, suggest

246 ancer, but the direct effect of androgens on cellular immunity remains largely uncharacterized.

247 pectives for differential shaping of desired cellular immunity required to fight the wide range of co

248 Adaptive cellular immunity requires accurate self- vs. nonself-di

249 , the preferential activation of humoral and cellular immunity, respectively.

250 nation strategies designed to elicit durable cellular immunity should target the generation of TSCM c

251 h emphasis on the tumor microenvironment and cellular immunity, taking into account novel nanotechnol

252 r induction of virus-specific antibodies and cellular immunity than would gD2t.

253 ork of Elie Metchnikoff and the discovery of cellular immunity, the phagocytic clearance of cellular

254 ty and impairment of CoV-2-specific Th1-type cellular immunity, thereby supporting a concept of alter

255 ral protection against pathogens and promote cellular immunity through diverse nonclassical effector

256 tibodies have important roles in controlling cellular immunity through interaction with activating or

257 Instead, IFITM3 promoted antiviral cellular immunity through the restriction of virus-induc

258 Although cellular immunity to acute lymphocytic choriomeningitis

259 is overlapping, and preexisting humoral and cellular immunity to both are exhibited in human populat

260 cPLA(2) in the induction of cell autonomous cellular immunity to Chlamydia and highlight the many no

261 s a major barrier limiting the capability of cellular immunity to contain infection and the ability o

262 This study investigates the contribution of cellular immunity to cross-protection using mouse models

263 Further, expecting cellular immunity to enhance chronic viremia control, we

264 may be required toward mechanisms that boost cellular immunity to gH and gL within future subunit vac

265 ntigen (HBsAg) sometimes develop humoral and cellular immunity to HBV proteins such as core and polym

266 The persistence of cellular immunity to mumps vaccine has not been defined.

267 difference in the development of humoral or cellular immunity to pneumococcal colonization between w

268 l much to learn about natural resistance and cellular immunity to pneumococcus.

269 vaccines should elicit effective humoral and cellular immunity to protect an individual from infectio

270 r data suggest that eosinophils promote host cellular immunity to reduce influenza virus replication

271 emory T cells (T(RM) cells) are critical for cellular immunity to respiratory pathogens and reside in

272 Moreover, cellular immunity to saliva or distinct salivary protein

273 Animals immunized with rat MAA developed cellular immunity to the antigen.

274 d intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis anti

275 sed adjuvant effects in boosting humoral and cellular immunity to vaccinia virus.

276 inants of the AAVrh32.33 capsid that augment cellular immunity to vector-encoded proteins or those of

277 s and altered long-term persistence of human cellular immunity to YF vaccination.

278 bination antiretroviral therapy, recovery of cellular immunity triggers inflammation to a preexisting

279 cus on humoral immunity, leaving the role of cellular immunity unclear.

280 a key autoantigen driving the Th17-dependent cellular immunity underlying another chronic inflammator

281 However, the ability to induce protective cellular immunity varies among rAds.

282 The ability to induce humoral and cellular immunity via antigen delivery through the unbro

283 rP18tri vector can induce strong humoral and cellular immunity via different immunization routes and

284 dherence to host cells, and modulating human cellular immunity via interactions with T cells and neut

285 rotection was mainly antibody dependent, but cellular immunity was also beneficial in protecting agai

286 Adaptive antiviral cellular immunity was increased in mCMV-infected VIP-KO

287 iculate vaccine adjuvant-induced Ag-specific cellular immunity was investigated.

288 In this system, female cellular immunity was more reactive to mating, and matin

289 Cellular immunity was reduced in parallel with depleted

290 To enhance cellular immunity, we further combined DJ NS1 with DENV

291 ymorphic due to the selective forces of host cellular immunity, we hypothesized that certain immune-e

292 ical anergy and other evidence of diminished cellular immunity, we hypothesized that decreased skin d

293 mechanisms underlying wasp virulence and fly cellular immunity, we used a joint transcriptomic/proteo

294 protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular imm

295 Also, few adjuvants induce strong cellular immunity, which is important for protection aga

296 ate a multifaceted immune response including cellular immunity, which may provide protection against

297 Aging leads to reduced cellular immunity with consequent increased rates of inf

298 1 vaccine is devising a strategy to generate cellular immunity with sufficient breadth to deal with t

299 of the CD40-CD154 immune pathway in boosting cellular immunity within epithelia.

300 an emerging technology to induce therapeutic cellular immunity without the need for autologous antige